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Background: Polymyxin B-immobilized fiber column hemoperfusion (PMX) has been reported to be effective for
patients with septic shock. It remains unclear, however, how the efficacy of PMX varies according to the characteristics
and underlying conditions of the patients treated. The objective of the present study was to clarify the factors that
result in clinical efficacy of PMX treatment.
Methods: We retrospectively investigated 78 consecutive patients with severe sepsis or septic shock who underwent
PMX treatment. We reviewed the demographic data, routine biochemistry, microbiological data, infection focus, Acute
Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score, change
in mean arterial pressure (MAP), inotropic score, vasopressor dependency index, plasma levels of endotoxin and lactate,
PaO2/FIO2 ratio, and survival time. We also divided the patients into two groups for comparison, namely, those whose
inotropic scores improved after PMX treatment (improvement group) and those whose inotropic scores did not
improve (non-improvement group).
Results: The inotropic score and the vasopressor dependency index significantly decreased from 18.1 to 9.9 (p < 0.05)
and from 0.27 to 0.14 (p < 0.05), respectively, after PMX treatment in the overall study population, while no significant
change in the PaO2/FIO2 ratio was observed (p = 0.96). The inotropic score at pre-PMX treatment was significantly
higher in the improvement group than in the non-improvement group (p < 0.01). The improvement of the PaO2/FIO2
ratio after PMX treatment was significant in the improvement group (p < 0.05).
Conclusions: The improvement group’s inotropic score was higher, because of peripheral blood vessels dilatation and
requirement for more catecholamines. Therefore, our study suggests that PMX treatment is particularly useful for
improving hemodynamics in septic shock patients with excessively dilated peripheral blood vessels.
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Septic shock is still a serious event associated with high
mortality and multiple organ failure in spite of ad-
vances in intensive therapy techniques and the intro-
duction of new drugs [1]. When a patient goes into
sepsis, endotoxin (lipopolysaccharide; LPS), a compo-
nent of the outer membrane of Gram-negative bacteria,
induces a very strong acute inflammatory response, stimu-
lates immunocompetent cells such as macrophages, and* Correspondence: sugipulm@tmd.ac.jp
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unless otherwise stated.activates inflammatory cytokines, platelet-activating factor,
and nitric oxide synthase. These changes often go on to
cause fatal circulatory failure and multiple organ fail-
ure. Polymyxin B-immobilized fiber column hemoper-
fusion (PMX) is a method to adsorb the circulating
endotoxin in blood by direct extracorporeal hemoper-
fusion without exerting toxicity [2]. This fiber column
covalently immobilizes polymyxin B, a cyclic polypep-
tide antibiotic, and binds to endotoxin [3]. The column
contains a sheet of braided fibers composed of polystyr-
ene on the outer portion of the sheet and polypropyl-
ene on the inner portion. Polystyrene fibers covalently
bind to polymyxin B, a strong LPS adsorber. Lipid A ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ionic bonding, or the hydrophobic moiety of LPS binds
to the hydrophobic chain of polymyxin B via hydropho-
bic bonding [3]. Hence, the endotoxin can be effectively
removed. Recent studies have also demonstrated the
ability of PMX to remove endogenous cannabinoids [4].
Other papers, meanwhile, report that the endotoxin re-
moval by PMX helps to reduce several other mediators
such as interleukin (IL)-6 [5,6], tumor necrosis factor
(TNF)-α [7], and tissue inhibitor of metalloproteinase 1
[8,9]. PMX was first developed in 1994 and has been
widely used in patients with septic shock in Japan. The
method is reportedly effective for both increasing the
mean arterial pressure (MAP) [10,11] and improving
PaO2/FIO2 in patients with septic shock [10]. Yet, in
spite of these reported benefits from PMX treatment,
the treatment has not conferred sufficient effects in pa-
tients with severe sepsis. Hence, it remains unclear how
the efficacy of PMX treatment varies according to the
characteristics and underlying conditions of the pa-
tients treated. The objective of the present study was to
clarify the factors that result in clinical efficacy of PMX
treatment.
Methods
This was a retrospective observational study conducted in
the intensive care unit (ICU) of Tokyo Medical and Dental
University between April 2004 and July 2013. The study
was approved by our Institutional Ethics Committee after
the patients or their families gave informed consent to a
review of patient records. We retrospectively reviewed
demographic data, routine biochemistry, microbiological
data, infection focus, the Acute Physiology and Chronic
Health Evaluation (APACHE) II score, the Sequential
Organ Failure Assessment (SOFA), and the survival time
of 78 consecutive patients with severe sepsis or septic
shock. The inclusion criteria for PMX treatment were se-
vere sepsis or septic shock with an increased plasma endo-
toxin concentration or suspected Gram-negative infection.
Severe sepsis was defined as sepsis plus sepsis-induced
acute organ dysfunction or tissue hypoperfusion second-
ary to documented or suspected infection. Septic shock
was defined as severe sepsis plus hypotension not reversed
with adequate fluid resuscitation [12].
The PMX treatment was administered by the following
method. A Toraymyxin 20-R cartridge (Toray Industries,
Tokyo, Japan) was washed by perfusion with 4 L of 0.9% sa-
line. After inserting a double-lumen catheter into a central
vein according to the Seldinger method, blood was drawn
from the proximal port, perfused through the Toraymyxin
20-R cartridge, and returned to the vein through the distal
port of the catheter. The perfusion was performed at a rate
of 80 to 100 mL/min using nafamostat mesilate protease
inhibitor (Torii Pharmaceuticals, Co., Ltd., Tokyo, Japan) asan anticoagulant. The PMX treatment was commenced
in the ICU within 24 h after diagnosis of severe sepsis
or septic shock and extended for as long as possible
beyond 2 h. The duration of PMX treatment was deter-
mined by consensus at a conference of attending physi-
cians, intensivists, and nephrologists. This duration
varied according to both the time of commencement of
treatment and the arrangements of the staff in the De-
partment of Blood Purification [13].
The assay for endotoxin was performed with separated
plasma from heparinized whole blood samples centrifuged
at 3,000 rpm for 40 s. The high-sensitivity assay was per-
formed by a kinetic turbidimetric Limulus assay using a
MT-358 Toxinometer (Wako Pure Chemical Industries,
Ltd., Osaka, Japan), a device theoretically capable of meas-
uring with an accuracy of up to 0.01 pg/mL. This Limulus
assay tests for a specific endotoxin and is confirmed not to
cross-react with β-glucan [14]. The cutoff endotoxin level
for the diagnosis of sepsis is 1.1 pg/mL. Changes in MAP
and the PaO2/FIO2 ratio were also evaluated. The inotropic
score was calculated as (dopamine dose × 1) + (dobutamine
dose × 1) + (adrenaline dose × 100) + (noradrenaline dose ×
100), where all doses are expressed as microgram per kilo-
gram per minute [10]. We also calculated the vasopressor
dependency index, which was the ratio of inotropic score
to MAP, because a dose-response relationship between
vasopressor dose and MAP has been used as the degree of
hemodynamic impairment [10]. All clinical data were re-
corded at baseline, at completion of the PMX treatment,
and at the time of death or hospital discharge.
The hemodynamics and respiratory status were assessed
before and immediately after the PMX treatment. Subse-
quently, all patients were separated into two groups for
analysis: improvement and non-improvement groups.
When the inotropic score before the PMX treatment
minus that after the PMX treatment was greater than 0,
patient was allocated to improvement group. When the
inotropic score before the PMX treatment minus that after
the PMX treatment was less than or equal to 0, patient
was allocated to non-improvement group. The reason why
we select the factor inotropic score is that this factor sig-
nificantly contributes to improve outcome in 28 days sur-
vival group by preliminary examination.
Statistical analysis
Continuous variables are presented as means and 95%
confidence intervals (CIs). Comparisons of continuous
variables between the two groups were conducted with
the Mann-Whitney U test. Inter-group comparisons of
categorical variables such as sex, history of diabetes, or
history of corticosteroid therapy were conducted with
the Fisher’s exact test. Comparisons among different
points (baseline and the time of finished the PMX treat-
ment) within groups were performed using a Wilcoxon
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culated from the date of ICU admission to the date of
death or the date of hospital discharge and analyzed by a
log-rank test. All statistical analyses were performed with
EZR (Saitama Medical Center, Jichi Medical University,
Saitama, Japan), a graphical user interface for R (The R
Foundation for Statistical Computing, Vienna, Austria).
More precisely, EZR is a modified version of R com-
mander designed to add statistical functions frequently
used in biostatistics. A p value of less than 0.05 was con-
sidered statistically significant.
Results
The characteristics of all patients are summarized in
Table 1. The median age was 70 years, and 50 of the 78
patients were male. Median total PMX treatment time
was 1,456 min. The sources of infection included ab-
dominal infection, bloodstream infection, respiratory in-
fection, urinary tract infection, and others (unknownTable 1 Patient characteristics at baseline
Case number 78 patients
Sex (male/female) 50/28
Age (years) 70 (20–87)
APACHE II score 24 (3–38)
SOFA score 11 (0–19)
MAP before the PMX treatment (mmHg) 64 (40–104)
CVP before the PMX treatment (mmHg) 15 (12–22)
Creatinine before the PMX treatment (mg/dl) 1.42 (0.41–10.24)
Endotoxin level before the PMX treatment (pg/mL) 11.3 (0.8–1925)
Lactate level before the PMX treatment (mmol/L) 3.7 (1.0–23.0)
Patients with diabetes mellitus 24
Patients received corticosteroid therapy 13
The times of PMX therapy 1 (1–6)











Others (unknown origin) 20
Data are presented as number of cases or median (range). MAP mean arterial
pressure, CVP central venous pressure, APACHE II Acute Physiology and
Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, PMX
polymyxin B-immobilized fiber column hemoperfusion, GNR Gram-negative
rods, GPC Gram-positive cocci, GPR Gram-positive rods.origin). Suspected causative microorganisms were shown
in Table 1. Gram-negative rods (GNR) include Escherichia
coli, Klebsiella pneumoniae, Psudomonas aeruginosa, Ser-
ratia marcescence, Acinetobacter baumanni, Stenotropho-
monas maltophilia, Enterobacter cloacae, Achromobacter
xylosoxidans, and Bacteroides fragilis; Gram-positive cocci
(GPC) include MRSA (Methicillin-resistant Staphylococ-
cus aureus), Enterococcus faecalis, Enterococcus faecium,
and group A streptococcus; and Gram-positive rods (GPR)
include Corynebacterium. All patients were followed-up
until death (n = 46) or hospital discharge (n = 32). Table 2
shows the changes in the inotropic score, the vasopressor
dependency index, and the PaO2/FIO2 ratio from baseline
to post-PMX in all patients. The inotropic score and the
vasopressor dependency index significantly decreased
from 18.1 to 9.9 (p < 0.05) and from 0.27 to 0.14 (p < 0.05),
respectively, after PMX treatment, while the PaO2/FIO2
ratio showed no significant change (p = 0.96). Table 3
shows the characteristics of the improvement and non-
improvement groups in this study. There were no
significant differences between the two groups in organ
dysfunction, MAP before the PMX treatment, chronic ill-
ness, the endotoxin level before and after the PMX treat-
ment, the times of PMX therapy, total PMX treatment
time, or the PaO2/FIO2 ratio before the PMX treatment.
The inotropic score and the vasopressor dependency
index before the PMX treatment, however, were signifi-
cantly higher in the improvement group than in the non-
improvement group. This meant that the improvement
group required large doses of catecholamine before the
PMX treatment. The PaO2/FIO2 ratio was also signifi-
cantly improved after PMX treatment in the improvement
group. The median survival time was shorter in the im-
provement group than in the non-improvement group,
but the difference was not significant. As for patients’ dis-
tribution, there were no significant differences in sus-
pected causative microorganisms between the two groups.
Actual mortality rate in the improvement group (50%)
was not significantly different from the predicted mortality
rate by APACHE II score (48.9%).
Discussion
The present study showed that the PMX treatment signi-
ficantly improved the median inotropic score and theTable 2 Changes in inotropic score and PaO2/FIO2 ratio
from pre-PMX to post-PMX
pre-PMX post-PMX p value
Inotropic score 18.1 (24.6) 9.9 (19.0) 0.011
PaO2/FIO2 ratio 201 (220) 205 (203) 0.956
Vasopressor dependency
index (/mmHg)
0.27 (0.34) 0.14 (0.27) 0.002
Data are presented as median. IQR interquartile range, PMX polymyxin
B-immobilized fiber column hemoperfusion.
Table 3 Patient characteristics of improvement group and non-improvement group
Improvement (n = 42) Non-improvement (n = 36) p value
Sex (male/female) 24/18 26/10 0.237
Age (years) 69 (13) 71 (34) 0.996
APACHE II score 24 (12) 24 (12) 0.980
SOFA score 11 (4) 11 (7) 0.996
MAP at baseline (mmHg) 62 (10) 72 (22) 0.343
Creatinine at baseline (mg/dl) 1.28 (1.72) 1.65 (1.85) 1.000
Lactate level at baseline (mmol/L) 3.2 (5.9) 4.2 (4.9) 0.599
Patients with diabetes mellitus 13 11 1.000
Patients received corticosteroid therapy 8 5 0.762
The times of PMX therapy 1 (1) 1 (1) 0.281
Total PMX treatment time (min) 1598 (2972) 1412 (2254) 0.237
Inotropic score at pre-PMX 24.7 (21.0) 10.3 (18.6) 0.001
Inotropic score at post-PMX 6.8 (15.6) 16.6 (32.8) 0.037
Vasopressor dependency index at pre-PMX (/mmHg) 0.33 (0.44) 0.19 (0.29) 0.019
Vasopressor dependency index at post-PMX(/mmHg) 0.13 (0.26) 0.14 (0.28) 0.845
PaO2/FIO2 ratio at pre-PMX 210 (234) 199 (206) 0.980
PaO2/FIO2 ratio at post-PMX 254 (181) 172 (156) 0.041
Endotoxin level before the PMX treatment (pg/mL) 15.8 (60.5) 6.1 (23.7) 0.195
Endotoxin level after the PMX treatment (pg/mL) 1.4 (18.2) 0.8 (0.7) 0.267
Suspected causative microorganisms (GNR/GPC/GPR/unknown origin) 24/6/2/10 17/6/0/13 0.428
Median survival time (days) 72 131 0.172
Ventilator-dependent time (days) 13 (33) 7 (42) 0.557
Data are presented as number of cases or median (IQR). IQR interquartile range, MAP mean arterial pressure, APACHE II Acute Physiology and Chronic Health
Evaluation II, SOFA Sequential Organ Failure Assessment, PMX polymyxin B-immobilized fiber column hemoperfusion, GNR Gram-negative rod, GPC Gram-positive
cocci, GPR Gram-positive rods.
Sugiura et al. Journal of Intensive Care  (2015) 3:14 Page 4 of 7vasopressor dependency index. The inotropic score has
been referred to as the vasopressor score [15], and these
scores are used for the vasopressor requirement. Dopa-
mine and norepinephrine have been used as vasopressor
therapy to restore and maintain blood pressure, although
the use of dopamine was associated with a greater number
of adverse events [16]. Both these agents influence alpha-
adrenergic and beta-adrenergic receptors, but to different
degrees. Alpha-adrenergic effect of norepinephrine is
greater than that of dopamine. In the present study, more
than half of the patients were treated with norepineph-
rine/dopamine or norepinephrine/dopamine/dobutamine,
but few patients were treated with norepinephrine alone,
suggesting that inotropic score more reflects the degree of
vasodilation rather than norepinephrine alone. Therefore,
we adopted inotropic score rather than norepinephrine
alone. We assessed hemodynamics by dividing all of pa-
tients into two groups, those whose inotropic scores im-
proved after the PMX treatment (improvement group)
and those whose inotropic scores did not improve (non-
improvement group). Next, we compared several factors
between the two groups to identify which factors con-
tributed to the improvement. We found no significantdifference between the groups when we compared the
status of immunosuppressive conditions by assessing, for
example, whether the patients received corticosteroid
therapy or had any history of diabetes mellitus or organ
dysfunction. There were no significant differences between
the two groups when we compared suspected causative
microorganisms and endotoxin levels. We also found,
however, that the inotropic score before the PMX treat-
ment was significantly higher in the improvement group
than in the non-improvement group. This was unex-
pected, as we had hypothesized that a better condition
before the PMX treatment brought about stronger effects
on hemodynamic status. The somewhat comparable MAP
values in the two groups indicated that the improvement
group required more catecholamines to achieve a blood
pressure equivalent to that of the non-improvement
group. In fact, the vasopressor dependency index before
the PMX treatment was significantly higher in the im-
provement group than in the non-improvement group.
Higher vasopressor dependency index means that more
vasopressors are required to increase 1 mmHg of MAP, in-
dicating peripheral vasodilatation. Hence, the peripheral
blood vessels are likely to have been more dilated in the
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warm (or hyperdynamic) shock and cold (or hypodynamic)
shock. Warm shock is characterized by high cardiac output
and low peripheral vascular resistance. Therefore, the im-
provement group may include many patients with warm
shock. The inotropic score was also found to decrease sig-
nificantly after the PMX treatment in the improvement
group. Of course, there may be some other possible mech-
anisms for improvement of hypotension. First, there may
be sepsis induced-cardiomyopathy. Although the patients
who required dobutamine were not so many, we did not
examine echocardiography in all patients. Accordingly, we
cannot completely deny sepsis-induced cardiomyopathy.
Second, there may be increased permeability-induced
intravascular hypovolemia. In early stage of sepsis, most of
the patients had received a lot of fluid for resuscitation.
Then, catecholamines were administered if the patients
had continuous hypotension. As shown in Table 1, central
venous pressure (CVP) was not low before the PMX treat-
ment. Therefore, it seems unlikely that intravascular hypo-
volemia exists in all patients before PMX treatment. These
findings, taken together, confirm that the PMX treat-
ment was one of the effective factors in constricting
the peripheral blood vessels. Earlier reports attribute
the hemodynamic improvement from PMX treatment
to the adsorption of anandamide (ANA) [4,17], 2-
arachidonylglycerol (2-AG) [17,18], and nitric oxide (NO)
[19]. ANA and 2-AG, two different endogenous cannabi-
noids, can be produced by activated macrophages and
platelets, respectively [17]. ANA and 2-AG may be para-
crine mediators of hypotension during shock that act via
cannabinoid receptor type 1 (CB1), a cannabinoid receptor
subtype localized in the peripheral vasculature. Several
studies have demonstrated that ANA and 2-AG can elicit
CB1-receptor-mediated hypotension in rats [4]. PMX is
known to adsorb not only endotoxin, but also ANA, a
molecule that induces hypotension during endotoxin
shock. Recent in vitro findings have demonstrated that
ANA in saline/ethanol and in serum is efficiently adsorbed
in a column of polymyxin B-immobilized fiber [18]. The
mechanism of interaction between ANA and polymyxin B
is believed to be hydrophobicity [18]. NO is characterized
as a major mediator responsible for vasodilation and a loss
of vascular responsiveness to catecholamines in endotoxin
shock [20]. Overproduction of NO by inducible NO syn-
thase plays an important role in the pathophysiology of
endotoxin shock [21]. NO is also produced by substances
such as toxic shock syndrome toxin-1 (TSST-1), an exo-
toxin of S. aureus, or by lipoteichoic acid, a component of
the cell wall of Gram-positive bacteria [22]. NO produced
in large quantities by such mechanisms dilates the periph-
eral blood vessels and induces shock. PMX treatment re-
portedly decreases NO breakdown products (NOx) in
urine [19]. As such, the inhibition of NO production byPMX treatment could prevent vasodilation and increase
blood pressure.
Turning to clinical data, the first randomized controlled
trial (RCT), a pilot study performed in six European aca-
demic medical centers in 2005, concluded that PMX treat-
ment is associated with improved hemodynamic status
and cardiac function [11]. As with previous reports, our
findings suggest that endocannabinoids and NO, a vaso-
dilator substance, are involved in the development of sep-
tic shock, and that their removal with PMX confers the
antihypotensive effect of PMX treatment.
The PaO2/FIO2 ratio did not significantly improve after
PMX treatment in the study population overall. When we
divided the patients into an improvement group and non-
improvement group, the PaO2/FIO2 ratio before PMX
treatment was similar between the two groups. After the
PMX treatment, however, the PaO2/FIO2 ratio decreased in
the non-improvement group and increased in the improve-
ment group. Hence, we inferred a slight association be-
tween the PMX treatment and improved PaO2/FIO2 ratio.
Previous studies reported that PMX treatment improved
pulmonary oxygenation in addition to hemodynamics [10].
One study demonstrated significant negative correlations
between the PaO2/FIO2 ratio and the concentrations of IL-
8 and neutrophil elastase in patients with septic shock [23].
Another study identified PMX-induced decreases of metal-
loproteinase 1 concentrations in patients with acute re-
spiratory distress syndrome [8]. The improved pulmonary
oxygenation conferred by PMX treatment may therefore
derive from decreases in adhesion molecules, IL-8, neutro-
phil elastase [23], metalloproteinase 9, or the tissue inhibi-
tor of metalloproteinase 1 [8]. This remains speculative,
however, as no mechanisms for such an action has been
unraveled. The EUPHAS study, a multicenter RCT per-
formed in ten Italian intensive care units in 2009, found
that PMX treatment brought about significant improve-
ments in MAP, vasopressor indication, organ failure sever-
ity, and the PaO2/FIO2 ratio (p = 0.049) [10].
PMX treatment had no significant effects on ventilator-
dependent time or survival time in this study, though the
hemodynamics clearly improved after the treatment in the
comparative analysis between the improvement and non-
improvement groups. We were fairly certain that systemic
treatments to improve other organ failure, inhibit inflam-
mation, etc. were required for the treatment of septic
shock in our patients, while PMX was helpful for improv-
ing hemodynamics.
Readers should be aware of several limitations of this
study. First, medical technologies and treatment modal-
ities changed considerably over the approximately 9 years
intervening between the first and last hospitalizations of
the study subjects. Intensive care techniques, drugs, and
various medical devices all advanced during this period
[1], and an influential report advocating a longer duration
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long period of patient collection were very likely to have
affected the data for this study. Second, this study was
retrospective. There are ethical and moral perils in allocat-
ing patients without PMX treatment, as PMX treatment
for septic shock is covered under the national health insur-
ance system in Japan. This disallows randomized control
trials in Japan; hence, many studies from Japan are retro-
spective case series with no control groups. The efficacy of
PMX treatment is being evaluated in two more multi-
center prospective RCT now underway, ABDO-MIX in
Europe and EUPHRATES in the USA [24]. The ABDO-
MIX study (ClinicalTrials.gov NCT01222663) is a French
RCT that evaluated 28-day mortality in patients with sep-
tic shock due to peritonitis. Eligible patients (n = 240) were
randomized to standard care versus standard care plus
PMX treatment within 36 h of abdominal surgery to repair
intestinal perforation. Although there was no significant
difference in mortality between the groups, the study had
a number of potential problems such as cartridge clotting
and higher failure rates. Therefore, these factors may de-
crease the power to detect a difference [25]. We are eager
to learn the results of the EUPHRATES study.
Conclusions
In sepsis cases, because of the peripheral blood vessels dila-
tion, the higher inotropic score means more requirement
of catecholamine. Our study suggested that PMX treat-
ment mainly helps for improvement of the hemodynamics
of septic shock patients. Particularly good effects seemed
to be achieved when peripheral blood vessels were exces-
sively dilated due to septic shock.
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